ABCD Trial Could Expand ICD Market If TWA Flies As A Stand-Alone Test
This article was originally published in The Gray Sheet
Executive Summary
The Alternans Before Cardioverter-Defibrillator (ABCD) trial could be the basis for a stand-alone indication for Cambridge Heart's microwave T-wave alternans (TWA) test, according to the company.
You may also be interested in...
MTWA Testing Would Lead To More ICD Referrals – Medtronic
Medtronic is sponsoring a registry to help determine whether microvolt T-wave alternans (MTWA) testing can identify post-MI patients with a left-ventricular ejection fraction (LVEF) of 30%-40% who are most likely to benefit from an ICD
MTWA Testing Would Lead To More ICD Referrals – Medtronic
Medtronic is sponsoring a registry to help determine whether microvolt T-wave alternans (MTWA) testing can identify post-MI patients with a left-ventricular ejection fraction (LVEF) of 30%-40% who are most likely to benefit from an ICD
T-Wave Alternans Will Help ICDs Meet Market Potential – Cambridge Heart
Further adoption of Cambridge Heart's Microvolt T-Wave Alternans (MTWA) non-invasive test for assessing risk of sudden cardiac death will boost the number of ICD-eligible patients referred to electrophysiologists, the company maintains